Literature DB >> 15213060

Downward resetting of the osmotic threshold for thirst in patients with SIADH.

D Smith1, K Moore, W Tormey, P H Baylis, C J Thompson.   

Abstract

The syndrome of inappropriate antidiuretic hormone (SIADH) is characterized by euvolemic hyponatremia. Patients with SIADH continue to drink normal amounts of fluid, despite plasma osmolalities well below the physiological osmotic threshold for onset of thirst. The regulation of thirst has not been previously studied in SIADH. We studied the characteristics of osmotically stimulated thirst and arginine vasopressin (AVP) secretion in eight subjects with SIADH and eight healthy controls and the nonosmotic suppression of thirst and AVP during drinking in the same subjects. Subjects underwent a 2-h infusion of hypertonic (855 mmol/l) NaCl solution, followed by 30 min of free access to water. Thirst rose significantly in both SIADH (1.5 +/- 0.6 to 8.0 +/- 1.2 cm, P < 0.0001) and controls (1.8 +/- 0.8 to 8.4 +/- 1.5 cm, P < 0.0001), but the osmotic threshold for thirst was lower in SIADH (264 +/- 5.5 vs. 285.9 +/- 2.8 mosmol/kgH(2)O, P < 0.0001). SIADH subjects drank volumes of water similar to controls after cessation of the infusion (948.8 +/- 207.6 vs. 1,091 +/- 184 ml, P = 0.23). The act of drinking suppressed thirst in both SIADH and controls but did not suppress plasma AVP concentrations in SIADH compared with controls (P = 0.007). We conclude that there is downward resetting of the osmotic threshold for thirst in SIADH but that thirst responds to osmotic stimulation and is suppressed by drinking around the lowered set point. In addition, we demonstrated that drinking does not completely suppress plasma AVP in SIADH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213060     DOI: 10.1152/ajpendo.00033.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  16 in total

1.  Clinical management of SIADH.

Authors:  Peter Gross
Journal:  Ther Adv Endocrinol Metab       Date:  2012-04       Impact factor: 3.565

Review 2.  Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).

Authors:  A Peri; N Pirozzi; G Parenti; F Festuccia; P Menè
Journal:  J Endocrinol Invest       Date:  2010-10-08       Impact factor: 4.256

3.  Current and future treatment options in SIADH.

Authors:  Robert Zietse; Nils van der Lubbe; Ewout J Hoorn
Journal:  NDT Plus       Date:  2009-11

Review 4.  Management of hyponatraemia in older people: old threats and new opportunities.

Authors:  Roy L Soiza; Hannah S C Talbot
Journal:  Ther Adv Drug Saf       Date:  2011-02

Review 5.  SIAD: practical recommendations for diagnosis and management.

Authors:  M Cuesta; A Garrahy; C J Thompson
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

6.  A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis.

Authors:  Wiebke Kristin Fenske; Mirjam Christ-Crain; Anna Hörning; Jessica Simet; Gabor Szinnai; Martin Fassnacht; Jonas Rutishauser; Daniel G Bichet; Stefan Störk; Bruno Allolio
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

Review 7.  Disturbances of sodium in critically ill adult neurologic patients: a clinical review.

Authors:  Martin Tisdall; Matthew Crocker; Jonathan Watkiss; Martin Smith
Journal:  J Neurosurg Anesthesiol       Date:  2006-01       Impact factor: 3.956

8.  Hyponatremia in patients with neurologic disorders.

Authors:  Dong Ki Kim; Kwon Wook Joo
Journal:  Electrolyte Blood Press       Date:  2009-12-31

9.  The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial.

Authors:  Judith E Heida; Ron T Gansevoort; Vicente E Torres; Olivier Devuyst; Ronald D Perrone; Jennifer Lee; Hui Li; John Ouyang; Arlene B Chapman
Journal:  J Am Soc Nephrol       Date:  2021-04-22       Impact factor: 14.978

Review 10.  Hyponatremia: Special Considerations in Older Patients.

Authors:  Roy L Soiza; Kirsten Cumming; Jennifer M Clarke; Karen M Wood; Phyo K Myint
Journal:  J Clin Med       Date:  2014-08-18       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.